No Study Name/Phase Type Sponsor Population (Gender/Age) Estimated target Period
1 HPV vaccine /Phase III HPV vaccine MSD ♀ 9-26 yrs 20 2010-2018
2 TB-018/Phase III TB Vaccine Aeras/GSK ♂/♀ 18-50 yrs 450  2014-2018
3 Menacwy/Phase III Menengococccal vaccine Pfizer ♂/♀ 12-14 M 80 2014-2019
4 ECHO/Phase III HIV risk with Contraception FHI360/UW ♀ 16-35 yrs 800  2015-2019
5 HVTN 100/Phase I/II (Part B) HIV Vaccine DAIDS ♂/♀ 18-35 yrs 12 2017 – 2019
6 RSV (Season 2)/Phase III RSV Vaccine Novavax ♀ 18-35 yrs 150 2016 -2018
7 RSV (Season 3)/Phase III RSV Vaccine Novavax ♀ 18-35 yrs 200 2017 -2019
8 HVTN702/Phase III HIV Vaccine DAIDS ♂/♀ 18-35 yrs 443 2017 -2020
9 HVTN108/PhaseI/IIa HIV Vaccine DAIDS ♂/♀ 18-35 yrs 16 2017 -2019
10 HDT TB/Phase II TB Treatment ACT4TB/ Aurum ♂/♀ 18-65 yrs 50 2016 – 2019
11 IMP-Atx/Phase II Impetigo Treatment AntibioTx ♂/♀ 9m – 70 yrs 15 2018